Masakazu Toi, MD, PhD

Director, Tokyo Metropolitan Cancer and Infectious Disease Center, Komagome Hospital, Tokyo, Japan

Dr. Toi is a Director at Tokyo Metropolitan Cancer and Infectious Disease Center, a high-volume center of Tokyo Metropolitan Government. Before, relocating to his current position, Dr. Toi was a senior physician scientist at the Graduate School of Medicine and Faculty of Medicine Kyoto University. Over the last few decades, he has been actively engaged in state-of-art breast cancer care, clinical trials, and translational breast cancer research with a particular focus on the tumor microenvironment and systemic responses. Dr. Toi earned his medical doctorate from Hiroshima University School of Medicine in 1982 and completed his Ph.D. in 1988. He continued his training in molecular biology and tumor angiogenesis at the Institute of Molecular Medicine of Oxford University, UK from 1990 to 1992. Soon after, Dr. Toi was appointed as an academic visitor to Prof. Adrian L Harr in the Department of Clinical Oncology, John- Radcliffe Hospital of Oxford University. From 1992 to 2007, Dr. Toi continued his clinical practice at Tokyo Metropolitan Cancer and Infectious Disease Center, a high-volume center of Tokyo Metropolitan Government. Soon after, Dr. Toi became the Director of Departments of Surgery and Clinical Trials. In 2000, as a Yamagiwa-Yoshida fellow of the UICC for advanced oncology experience, Dr. Toi visited the Department of Breast Medical Oncology, Dana-Farber Cancer Institute, Harvard University. He was also instrumental in shaping many aspects of Society-Academia Collaboration for Innovation of Kyoto University from 2016 to 2018 as its Deputy Director. Dr. Toi has been undertaking clinical trials for new generations of therapeutics and diagnostics. He has published more than 1000 papers in English and Japanese. Dr. Toi received the SGH special award in 2021 and is currently serving as the Chairman of the Japanese Breast Cancer Society.